.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy

June 2, 2013

Conferences | ASCO: American Society of Clinical Oncology

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment. He suggests that more careful healthcare spending could support the high costs, and deliver the potential benefits of these drug combinations. "This situation is not unique to breast cancer," said Kolodziej. "You can extrapolate it to just about any disease we treat these days.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.